Methods of treating disorders in which TFN.alpha. activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor .alpha. (hTNF.alpha.) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF.alpha. (e.g., K d = 10 -8 M or less), a slow off rate for hTNF.alpha. dissociation (e.g., K off = 10 -3 sec-1 or less) and neutralize hTNF.alpha. activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
